934664-22-9 Usage
Uses
Used in Pharmaceutical and Medicinal Research:
1-Oxa-5-azaspiro[2.3]hexane-5-carboxylic acid phenylmethyl ester is used as a research compound for exploring its potential biological activity and therapeutic applications. Its unique structure may offer novel interactions with biological targets, leading to the development of new drugs or therapeutic agents.
Used in Organic Synthesis:
In the field of organic chemistry, 1-Oxa-5-azaspiro[2.3]hexane-5-carboxylic acid phenylmethyl ester is used as a building block for the synthesis of other organic compounds. Its phenylmethyl ester group can be utilized in various chemical reactions to create new molecules with potential applications in different industries.
Used in Drug Development:
1-Oxa-5-azaspiro[2.3]hexane-5-carboxylic acid phenylmethyl ester is used as a lead compound in drug development. Its unique structure and potential biological activity may be harnessed to design and develop new pharmaceuticals with improved efficacy and selectivity.
Check Digit Verification of cas no
The CAS Registry Mumber 934664-22-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,3,4,6,6 and 4 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 934664-22:
(8*9)+(7*3)+(6*4)+(5*6)+(4*6)+(3*4)+(2*2)+(1*2)=189
189 % 10 = 9
So 934664-22-9 is a valid CAS Registry Number.
934664-22-9Relevant academic research and scientific papers
METHODS OF USING MEK INHIBITORS
-
Page/Page column 329-330, (2008/12/06)
The present invention provides methods of treating cancer by administering a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, in combination with other cancer treatments.
METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS
-
Page/Page column 180, (2008/12/04)
A method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a MEK compound of Formula I(M), or a pharmaceutical composition comprising a therapeutically effective amount of a MEK compound of Formula I(M) and a pharmaceutically acceptable carrier, in combination with a therapeutically effective amount of a JAK-2 compound of Formula I(J), or a pharmaceutical composition comprising a therapeutically effective amount of a JAK-2 compound of Formula I(J) and a pharmaceutically acceptable carrier, wherein the MEK compound of Formula I(M) and JAK-2 compound of Formula I(J) are as defined in the specification.
